Page last updated: 2024-08-25

methotrexate and Benign Monoclonal Gammopathies

methotrexate has been researched along with Benign Monoclonal Gammopathies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Asano, T; Fujita, Y; Matsumoto, H; Matsuoka, N; Migita, K; Ohkawara, H; Saito, K; Sato, S; Sumichika, Y; Temmoku, J; Watanabe, H; Yashiro-Furuya, M; Yoshida, S1
Chiarolanza, I; Di Lernia, V; Ficarelli, E; Lallas, A; Possemato, N; Salvarani, C1

Other Studies

2 other study(ies) available for methotrexate and Benign Monoclonal Gammopathies

ArticleYear
Refractory adult-onset Still's disease complicated with monoclonal gammopathy of undetermined significance: A case report.
    Medicine, 2022, Dec-09, Volume: 101, Issue:49

    Topics: Cytokines; Exanthema; Humans; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Still's Disease, Adult-Onset

2022
Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2015, Volume: 29, Issue:11

    Topics: Acitretin; Adalimumab; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclosporine; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Prevalence; Psoriasis; Tumor Necrosis Factor-alpha

2015